AbbVie Inc.
SELECTIVE BCL-2 INHIBITORS IN COMBINATION WITH AN ANTI-PD-1 OR AN ANTI-PD-L1 ANTIBODY FOR THE TREATMENT OF CANCERS

Abstract:

This invention pertains to a method for the treatment of cancer in a subject comprising administering to the subject an effective amount of a selective BCL-2 inhibitor or a prodrug or pharmaceutically acceptable salt thereof in combination with an effective amount of an anti-PD-1 antibody or an anti-PD-L1 antibody.